$2,580,000 of AMGEN INC lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions. Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to pediatric priority review voucher reauthorization HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 2214 DRUG Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act Issues related to drug pricing Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 946 Optimizing Research Progress Hope and New Cures Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income HR 1328 Supply Chain Security and Growth Act of 2025 HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to patent thickets/product hopping Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes Issues related to tariffs."
You can find more data on corporate lobbying on Quiver Quantitative.
AMGN Congressional Stock Trading
Members of Congress have traded $AMGN stock 7 times in the past 6 months. Of those trades, 5 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 3 times. They made 3 purchases worth up to $45,000 on 09/11, 05/14, 05/05 and 0 sales.
- SENATOR SHELDON WHITEHOUSE sold up to $15,000 on 09/04.
- REPRESENTATIVE LISA C. MCCLAIN purchased up to $15,000 on 06/24.
- REPRESENTATIVE CLIFF BENTZ purchased up to $15,000 on 06/06.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AMGN Insider Trading Activity
AMGN insiders have traded $AMGN stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by insiders over the last 6 months:
- RACHNA KHOSLA (SVP, Business Development) sold 1,500 shares for an estimated $434,520
- NANCY A. GRYGIEL (SVP & CCO) sold 1,267 shares for an estimated $376,279
- MATTHEW C. BUSCH (VP, Finance & CAO) sold 1,000 shares for an estimated $279,690
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AMGN Hedge Fund Activity
We have seen 1,304 institutional investors add shares of AMGN stock to their portfolio, and 1,278 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 3,775,911 shares (+24.9%) to their portfolio in Q2 2025, for an estimated $1,054,272,110
- PRIMECAP MANAGEMENT CO/CA/ removed 1,756,586 shares (-14.2%) from their portfolio in Q2 2025, for an estimated $490,456,377
- BLACKROCK, INC. added 1,158,907 shares (+2.6%) to their portfolio in Q2 2025, for an estimated $323,578,423
- TWO SIGMA ADVISERS, LP removed 997,300 shares (-99.6%) from their portfolio in Q2 2025, for an estimated $278,456,133
- PRICE T ROWE ASSOCIATES INC /MD/ removed 895,054 shares (-43.9%) from their portfolio in Q2 2025, for an estimated $249,908,027
- VANGUARD GROUP INC added 841,117 shares (+1.6%) to their portfolio in Q2 2025, for an estimated $234,848,277
- DEUTSCHE BANK AG\ removed 737,799 shares (-22.6%) from their portfolio in Q2 2025, for an estimated $206,000,858
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AMGN Analyst Ratings
Wall Street analysts have issued reports on $AMGN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Underperform" rating on 09/26/2025
- Piper Sandler issued a "Overweight" rating on 06/27/2025
- RBC Capital issued a "Outperform" rating on 05/02/2025
To track analyst ratings and price targets for AMGN, check out Quiver Quantitative's $AMGN forecast page.
AMGN Price Targets
Multiple analysts have issued price targets for $AMGN recently. We have seen 9 analysts offer price targets for $AMGN in the last 6 months, with a median target of $310.0.
Here are some recent targets:
- Tim Anderson from B of A Securities set a target price of $272.0 on 09/26/2025
- David Amsellem from Piper Sandler set a target price of $342.0 on 08/25/2025
- Terence Flynn from Morgan Stanley set a target price of $333.0 on 08/06/2025
- Trung Huynh from UBS set a target price of $317.0 on 08/06/2025
- Geoff Meacham from Citigroup set a target price of $310.0 on 08/06/2025
- Carter Gould from Cantor Fitzgerald set a target price of $305.0 on 06/24/2025
- Vamil Divan from Guggenheim set a target price of $288.0 on 05/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
